FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816553/33525/en/FibroGen-Announces-Completion-of-the-Pamrevlumab-Arm-in-Precision-Promise-Pancreatic-Cancer-Action-Network-s-Phase-2-3-Adaptive-Platform-Trial-for-Metastatic-Pancreatic-Cancer.html

SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline data from this registration study is anticipated in the second quarter of 2024.

Read more at globenewswire.com

Related news for (FGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.